0001415889-24-008561.txt : 20240319
0001415889-24-008561.hdr.sgml : 20240319
20240319163653
ACCESSION NUMBER: 0001415889-24-008561
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240315
FILED AS OF DATE: 20240319
DATE AS OF CHANGE: 20240319
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stevens Raymond C
CENTRAL INDEX KEY: 0001698149
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41608
FILM NUMBER: 24764006
MAIL ADDRESS:
STREET 1: 2200 PENNSYLVANIA AVENUE
STREET 2: SUITE 800W
CITY: WASHINGTON
STATE: DC
ZIP: 20037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Structure Therapeutics Inc.
CENTRAL INDEX KEY: 0001888886
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 981480821
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 611 GATEWAY BLVD SUITE 223
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (628) 229-9277
MAIL ADDRESS:
STREET 1: 611 GATEWAY BLVD SUITE 223
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: ShouTi Inc.
DATE OF NAME CHANGE: 20211019
4
1
form4-03192024_080344.xml
X0508
4
2024-03-15
0001888886
Structure Therapeutics Inc.
GPCR
0001698149
Stevens Raymond C
C/O STRUCTURE THERAPEUTICS INC.
601 GATEWAY BLVD., SUITE 900
SOUTH SAN FRANCISCO
CA
94080
true
true
false
false
CHIEF EXECUTIVE OFFICER
0
Ordinary Shares
2024-03-15
4
A
0
134682
0
A
1198346
D
Ordinary Shares
1554586
I
See footnote
Stock Option (right to buy)
35.25
2024-03-15
4
A
0
335481
0
A
2034-03-14
Ordinary Shares
335481
335481
D
Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2024, subject to Reporting Person's continued service on such dates.
By Raymond Stevens and Vivian Urena-Stevens, as Co-Trustees of the Stevens 2001 Revocable Trust, dated March 28, 2001.
1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.
/s/ Jun Yoon, Attorney-in-Fact
2024-03-19